S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PLSE

Pulse Biosciences Stock Forecast, Price & News

$25.68
+0.53 (+2.11 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.20
Now: $25.68
$25.98
50-Day Range
$24.86
MA: $33.68
$44.27
52-Week Range
$5.11
Now: $25.68
$45.82
Volume270,413 shs
Average Volume175,754 shs
Market Capitalization$650.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Pulse Biosciences logo

Headlines

Pulse Biosciences, Inc. Announces Redemption of Warrants
January 5, 2021 |  finance.yahoo.com
Stock Alert: Pulse Biosciences Jumps 23%
October 5, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLSE
CUSIPN/A
Phone510-906-4600
Employees82
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.48 per share

Profitability

Net Income$-46,970,000.00

Miscellaneous

Market Cap$650.78 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

457th out of 1,972 stocks

Surgical & Medical Instruments Industry

42nd out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$25.68
+0.53 (+2.11 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLSE News and Ratings via Email

Sign-up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions

Is Pulse Biosciences a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Pulse Biosciences stock.
View analyst ratings for Pulse Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pulse Biosciences?

Wall Street analysts have given Pulse Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pulse Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pulse Biosciences?

Pulse Biosciences saw a decline in short interest in the month of January. As of January 29th, there was short interest totaling 1,250,000 shares, a decline of 22.4% from the January 14th total of 1,610,000 shares. Based on an average daily trading volume, of 134,200 shares, the short-interest ratio is presently 9.3 days. Approximately 9.9% of the company's shares are short sold.
View Pulse Biosciences' Short Interest
.

When is Pulse Biosciences' next earnings date?

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Pulse Biosciences
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) issued its earnings results on Sunday, February, 21st. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.09.
View Pulse Biosciences' earnings history
.

How has Pulse Biosciences' stock been impacted by Coronavirus (COVID-19)?

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PLSE shares have increased by 303.8% and is now trading at $25.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PLSE?

1 Wall Street analysts have issued 1 year price targets for Pulse Biosciences' shares. Their forecasts range from $46.00 to $46.00. On average, they expect Pulse Biosciences' share price to reach $46.00 in the next year. This suggests a possible upside of 79.1% from the stock's current price.
View analysts' price targets for Pulse Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the following people:
  • Mr. Darrin R. Uecker, Pres, CEO & Director (Age 55, Pay $1.42M)
  • Ms. Sandra A. Gardiner, Exec. VP of Fin. & Admin., CFO, Sec. and Treasurer (Age 55, Pay $90.26k)
  • Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 61, Pay $419.85k)
  • Dr. Richard Nuccitelli Ph.D., Chief Science Officer
  • Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
  • Ms. Patty Perla, VP of HR

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences CEO Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among Pulse Biosciences' employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pulse Biosciences' key competitors?

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), (CGC), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.48%), Northern Trust Corp (0.94%), Griffin Asset Management Inc. (0.34%), Nuveen Asset Management LLC (0.24%), Bank of New York Mellon Corp (0.15%) and Charles Schwab Investment Management Inc. (0.13%).
View institutional ownership trends for Pulse Biosciences
.

Which major investors are selling Pulse Biosciences stock?

PLSE stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, BlackRock Inc., Wells Fargo & Company MN, Westside Investment Management Inc., Barclays PLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Pulse Biosciences
or view top insider-selling stocks.

Which major investors are buying Pulse Biosciences stock?

PLSE stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vontobel Holding Ltd., Griffin Asset Management Inc., Wolverine Trading LLC, The Manufacturers Life Insurance Company , Spotlight Asset Group Inc., Charles Schwab Investment Management Inc., and New York State Common Retirement Fund.
View insider buying and selling activity for Pulse Biosciences
or or view top insider-buying stocks.

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $25.68.

How much money does Pulse Biosciences make?

Pulse Biosciences has a market capitalization of $650.78 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Pulse Biosciences have?

Pulse Biosciences employs 82 workers across the globe.

What is Pulse Biosciences' official website?

The official website for Pulse Biosciences is www.pulsebiosciences.com.

Where are Pulse Biosciences' headquarters?

Pulse Biosciences is headquartered at 3957 POINT EDEN WAY, HAYWARD CA, 94545.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.